| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $537.7M | +256.6% |
| SG&A Expense | $556.8M | +819.8% |
| Pre-tax Income | -$1.08B | -387.8% |
| Income Tax | $0 | — |
| Net Income | -$1.08B | -387.8% |
| EPS (Basic) | -$1.44 | -364.5% |
| EPS (Diluted) | -$1.44 | -364.5% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $225.3M | +114.8% |
| Short-term Investments | $488.2M | +58.8% |
| Current Assets | $720.3M | +70.0% |
| Total Assets | $751.2M | +72.5% |
| Current Liabilities | $73.0M | +74.9% |
| Total Liabilities | $92.3M | +97.2% |
| Stockholders' Equity | $658.9M | +69.5% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$322.9M | -127.2% |
| Capital Expenditures | $657K | +372.7% |
| Investing Cash Flow | -$174.3M | +15.1% |
| Financing Cash Flow | $617.5M | +62.0% |
| Free Cash Flow | -$323.6M | -127.5% |